These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25078042)

  • 1. Coexisting irritable bowel-like symptoms in inflammatory bowel disease in remission is associated with impaired social functioning and increased bodily pain.
    Jelsness-Jørgensen LP; Bernklev T; Moum B
    Gastroenterol Nurs; 2014; 37(4):280-7. PubMed ID: 25078042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of IBS-like symptoms in patients with ulcerative colitis in clinical remission.
    Jonefjäll B; Strid H; Ohman L; Svedlund J; Bergstedt A; Simren M
    Neurogastroenterol Motil; 2013 Sep; 25(9):756-e578. PubMed ID: 23731196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease.
    Gracie DJ; Williams CJ; Sood R; Mumtaz S; Bholah MH; Hamlin PJ; Ford AC
    Clin Gastroenterol Hepatol; 2017 Mar; 15(3):376-384.e5. PubMed ID: 27189912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission.
    Hoekman DR; Zeevenhooven J; D'Haens GR; Benninga MA
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1086-1090. PubMed ID: 28639969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatigue and disease-related worries among inflammatory bowel disease patients in remission; is it a reflection of coexisting IBS-like symptoms? A short report.
    Jelsness-Jørgensen LP; Bernklev T; Moum B
    J Psychosom Res; 2012 Dec; 73(6):469-72. PubMed ID: 23148817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of irritable bowel syndrome-like symptoms using Rome IV criteria in patients with inactive inflammatory bowel disease and relation with quality of life.
    Ozer M; Bengi G; Colak R; Cengiz O; Akpinar H
    Medicine (Baltimore); 2020 May; 99(19):e20067. PubMed ID: 32384473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EHealth: self-management in inflammatory bowel disease and in irritable bowel syndrome using novel constant-care web applications. EHealth by constant-care in IBD and IBS.
    Pedersen N
    Dan Med J; 2015 Dec; 62(12):B5168. PubMed ID: 26621403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ulcerative colitis and irritable bowel syndrome: relationships with quality of life.
    Ansari R; Attari F; Razjouyan H; Etemadi A; Amjadi H; Merat S; Malekzadeh R
    Eur J Gastroenterol Hepatol; 2008 Jan; 20(1):46-50. PubMed ID: 18090990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease, and the relationship with biochemical markers of disease activity.
    Diederen K; Hoekman DR; Hummel TZ; de Meij TG; Koot BG; Tabbers MM; Vlieger AM; Kindermann A; Benninga MA
    Aliment Pharmacol Ther; 2016 Jul; 44(2):181-8. PubMed ID: 27110920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of irritable bowel syndrome-like symptoms in quiescent inflammatory bowel disease.
    Ahmed M; Pu A; Jencks K; Bishu S; Higgins P; Chey WD; Rao K; Lee A
    Neurogastroenterol Motil; 2024 Jun; 36(6):e14809. PubMed ID: 38651743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with longstanding ulcerative colitis in remission do not have more irritable bowel syndrome-like symptoms than controls.
    Lundgren D; Rutegård J; Eklöf V; Palmqvist R; Karling P
    BMC Gastroenterol; 2016 Nov; 16(1):139. PubMed ID: 27881072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal Calprotectin and serum chromogranin A as potential biomarkers of irritable bowel syndrome symptom severity.
    Pletikosic S; Plavsic I; Hauser G; Tkalcic M
    Med Hypotheses; 2015 Sep; 85(3):339-42. PubMed ID: 26112162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.
    Silberer H; Küppers B; Mickisch O; Baniewicz W; Drescher M; Traber L; Kempf A; Schmidt-Gayk H
    Clin Lab; 2005; 51(3-4):117-26. PubMed ID: 15819166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory bowel disease, irritable bowel syndrome, or what?: A challenge to the functional-organic dichotomy.
    Long MD; Drossman DA
    Am J Gastroenterol; 2010 Aug; 105(8):1796-8. PubMed ID: 20686466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
    Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
    Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain.
    Akbar A; Yiangou Y; Facer P; Brydon WG; Walters JR; Anand P; Ghosh S
    Gut; 2010 Jun; 59(6):767-74. PubMed ID: 20551462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
    Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D
    Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation.
    Vivinus-Nébot M; Frin-Mathy G; Bzioueche H; Dainese R; Bernard G; Anty R; Filippi J; Saint-Paul MC; Tulic MK; Verhasselt V; Hébuterne X; Piche T
    Gut; 2014 May; 63(5):744-52. PubMed ID: 23878165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in the health-related quality of life, affective status, and personality between irritable bowel syndrome and inflammatory bowel disease patients.
    Tkalcić M; Hauser G; Stimac D
    Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):862-7. PubMed ID: 19701092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of abuse and mood on bowel symptoms and health-related quality of life in irritable bowel syndrome (IBS).
    Kanuri N; Cassell B; Bruce SE; White KS; Gott BM; Gyawali CP; Sayuk GS
    Neurogastroenterol Motil; 2016 Oct; 28(10):1508-17. PubMed ID: 27151081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.